U.S. patent application number 12/388451 was filed with the patent office on 2009-08-20 for pneumostoma management method for the treatment of chronic obstructive pulmonary disease.
This patent application is currently assigned to Portaero, Inc.. Invention is credited to Richard A. Abraham, Gary L. Boseck, Jeffrey C. Cerier, Stephen C. Evans, David C. Plough, Don Tanaka, Joshua P. Wiesman.
Application Number | 20090205645 12/388451 |
Document ID | / |
Family ID | 40953964 |
Filed Date | 2009-08-20 |
United States Patent
Application |
20090205645 |
Kind Code |
A1 |
Tanaka; Don ; et
al. |
August 20, 2009 |
PNEUMOSTOMA MANAGEMENT METHOD FOR THE TREATMENT OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
Abstract
A method for maintaining the patency of a pneumostoma while
controlling the flow of material through the pneumostoma. A
pneumostoma management system includes a two-part pneumostoma
management device and associated insertion and removal tools. The
pneumostoma management device includes a pneumostoma vent and a
chest mount for positioning and securing the vent into a
pneumostoma. To use the system, the chest is first cleaned and the
chest mount secured to the chest adjacent the pneumostoma. The
pneumostoma vent is then inserted into the pneumostoma through an
aperture in the chest mount until it is engaged and secured by a
coupling of the chest mount. The pneumostoma vent may be replaced
periodically such as daily. The chest mount may be changed less
frequently such as weekly.
Inventors: |
Tanaka; Don; (Saratoga,
CA) ; Wiesman; Joshua P.; (Boston, MA) ;
Plough; David C.; (Portola Valley, CA) ; Cerier;
Jeffrey C.; (Franklin, MA) ; Abraham; Richard A.;
(Reading, MA) ; Evans; Stephen C.; (Westford,
MA) ; Boseck; Gary L.; (Belmont, CA) |
Correspondence
Address: |
FLIESLER MEYER LLP
650 CALIFORNIA STREET, 14TH FLOOR
SAN FRANCISCO
CA
94108
US
|
Assignee: |
Portaero, Inc.
Cupertino
CA
|
Family ID: |
40953964 |
Appl. No.: |
12/388451 |
Filed: |
February 18, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61029830 |
Feb 19, 2008 |
|
|
|
61032877 |
Feb 29, 2008 |
|
|
|
61038371 |
Mar 20, 2008 |
|
|
|
61082892 |
Jul 23, 2008 |
|
|
|
61083573 |
Jul 25, 2008 |
|
|
|
61084559 |
Jul 29, 2008 |
|
|
|
61088118 |
Aug 12, 2008 |
|
|
|
61143298 |
Jan 8, 2009 |
|
|
|
61151581 |
Feb 11, 2009 |
|
|
|
Current U.S.
Class: |
128/200.24 |
Current CPC
Class: |
A61B 2017/00809
20130101; A61M 16/0833 20140204; A61M 25/10 20130101; A61M 2205/075
20130101; A61M 2202/064 20130101; A61M 15/009 20130101; A61M
16/0816 20130101; A61M 16/202 20140204; A61M 2205/7518 20130101;
A61M 13/00 20130101; A61K 9/007 20130101; A61M 25/02 20130101; A61M
11/042 20140204; A61M 25/04 20130101; A61M 39/02 20130101; A61M
1/04 20130101; A61M 2039/0276 20130101; A61M 2202/0208 20130101;
A61M 2205/7536 20130101; A61M 2039/0252 20130101; A61M 39/0247
20130101; A61M 27/00 20130101; A61M 11/00 20130101; A61M 15/0085
20130101; A61M 15/02 20130101; A61M 2202/025 20130101; A61M 11/005
20130101 |
Class at
Publication: |
128/200.24 |
International
Class: |
A61M 16/00 20060101
A61M016/00 |
Claims
1. A method to control material entering and exiting a pneumostoma
on a chest of a patient using a disposable pneumostoma management
system having a chest mount and a pneumostoma vent wherein the
method comprises: (a) securing the chest mount to the chest of the
patient using an adhesive such that an aperture of the chest mount
is aligned with the pneumostoma; (b) inserting the pneumostoma vent
through the aperture of the chest mount into the pneumostoma and
securing the pneumostoma vent to the chest mount; (c) removing the
pneumostoma vent from the pneumostoma through the aperture of the
chest mount and inserting a second pneumostoma vent through the
aperture of the chest mount into the pneumostoma and securing the
second pneumostoma vent to the chest mount.
2. The method of claim 1, further comprising the step of: (d)
removing the chest mount from the chest of the patient after step
(c) and no sooner than two days after securing the chest mount to
the chest of the patient.
3. The method of claim 1, wherein approximately one day passes
between step (b) and step (c).
4. The method of claim 1, wherein step (c) comprises: (c1) removing
the pneumostoma vent from the pneumostoma through the aperture of
the chest mount and inserting a second pneumostoma vent through the
aperture of the chest mount into the pneumostoma and securing the
second pneumostoma vent to the chest mount; and (c2) removing the
second pneumostoma vent from the pneumostoma through the aperture
of the chest mount and inserting a third pneumostoma vent through
the aperture of the chest mount into the pneumostoma and securing
the third pneumostoma vent to the chest mount.
5. The method of claim 4, wherein approximately one day passes
between step (b) and step (c1) and between step (c1) and step
(c2).
6. The method of claim 5, further comprising the step of: (d)
removing the chest mount from the chest of the patient after step
(c2) and no sooner than 3 days after securing the chest mount to
the chest of the patient.
7. The method of claim 6, further comprising the step of: (e)
replacing the chest mount with a second chest mount.
8. A method to control material entering and exiting a pneumostoma
on a chest of a patient comprising: (a) selecting a pneumostoma
management device wherein the pneumostoma management device
comprises a chest mount and a pneumostoma vent, the chest mount
having a first coupling adjacent an aperture in the chest mount,
the pneumostoma vent having a tube connected to a flow control
device positioned such that material passing through the tube must
pass through the flow control device, and the pneumostoma vent
having a second coupling adapted to releasably engage the first
coupling; (b) securing the chest mount to the chest of the patient
such that aperture is aligned with the pneumostoma; (c) inserting
the tube of the pneumostoma vent through the aperture into the
pneumostoma and engaging the first coupling with the second
coupling such that the pneumostoma vent is secured in the
pneumostoma and such that material entering or exiting the
pneumostoma must pass through the tube and flow control device of
the pneumostoma vent.
9. The method of claim 8, wherein the chest mount comprises an
adhesive positioned to secure the chest mount to the chest of the
patient and wherein step (b) comprises: (b) securing the flange of
the pneumostoma management device to the chest of a patient with
the adhesive such that aperture is aligned with the
pneumostoma.
10. The method of claim 8, wherein the chest mount comprises a
hydrocolloid adhesive positioned to secure the chest mount to the
chest of the patient and wherein step (b) comprises: (b) securing
the chest mount of the pneumostoma management device to the chest
of a patient with a hydrocolloid adhesive such that aperture is
aligned with the pneumostoma.
11. The method of claim 8, wherein the chest mount is adapted to
conform to the chest of the patient and wherein step (b) comprises:
(b) securing the chest mount of the pneumostoma management device
to the chest of a patient by conforming the chest mount to the
chest of the patient such that aperture is aligned with the
pneumostoma.
12. The method of claim 8, further comprising: (d) disengaging the
second coupling from the first coupling and removing the
pneumostoma vent from the pneumostoma while leaving the chest mount
secured to the chest of the patient.
13. The method of claim 8, further comprising: (d) disengaging the
second coupling from the first coupling and removing the
pneumostoma vent from the pneumostoma while leaving the chest mount
secured to the chest of the patient; and (e) inserting a tube of a
second pneumostoma vent through the aperture and engaging the first
coupling with a second coupling of the second pneumostoma vent such
that the second pneumostoma vent is secured in the pneumostoma and
such that material entering or exiting the pneumostoma must pass
through a tube and flow control device of the second pneumostoma
vent.
14. The method of claim 12, further comprising the step of: (f)
removing the chest mount from the chest of the patient after step
(e) and no sooner than two days after securing the chest mount to
the chest of the patient.
15. The method of claim 1, wherein approximately one day passes
between step (c) and step (d) two or more times.
16. The method of claim 13, further comprising the step of
repeating steps (d) and (e).
17. The method of claim 16, further comprising the step of: (f)
removing the chest mount from the chest of the patient after said
repeating of steps (d) and (e) and no sooner than three days after
securing the chest mount to the chest of the patient.
18. The method of claim 17, further comprising the step of: (g)
replacing the chest mount with a second chest mount.
19. A method to control material entering and exiting a pneumostoma
on a chest of a patient comprising: (a) selecting a pneumostoma
management device wherein the pneumostoma management device
comprises a chest mount and a pneumostoma vent; the chest mount
having a first coupling adjacent an aperture in a flange; the
pneumostoma vent having a tube connected to a cap; the tube
connected to a flow control device positioned such that material
passing through the tube must pass through the flow control device;
the cap having a second coupling that can be releasably engaged
with the first coupling; (b) securing the flange to the chest of
the patient such that aperture is aligned with the pneumostoma; (c)
inserting the tube of the pneumostoma vent through the aperture and
engaging the first coupling with the second coupling such that the
pneumostoma vent is secured in the pneumostoma and such that
material entering or exiting the pneumostoma must pass through the
tube and flow control device of the pneumostoma vent.
20. The method of claim 19, wherein the flange comprises an
adhesive positioned to secure the flange to the chest of the
patient and wherein step (b) comprises: (b) securing the flange of
the pneumostoma management device to the chest of a patient with
the adhesive such that aperture is aligned with the
pneumostoma.
21. The method of claim 19, wherein the flange comprises a
hydrocolloid adhesive positioned to secure the flange to the chest
of the patient and wherein step (b) comprises: (b) securing the
flange of the pneumostoma management device to the chest of a
patient with a hydrocolloid adhesive such that aperture is aligned
with the pneumostoma.
22. The method of claim 19, wherein the flange is adapted to
conform to the chest of the patient and wherein step (b) comprises:
(b) securing the flange of the pneumostoma management device to the
chest of a patient by conforming the flange to the chest of the
patient such that aperture is aligned with the pneumostoma.
23. The method of claim 19, further comprising: (d) disengaging the
second coupling from the first coupling and removing the
pneumostoma vent from the pneumostoma while leaving the chest mount
secured to the chest of the patient.
24. The method of claim 19, further comprising: (d) disengaging the
second coupling from the first coupling and removing the
pneumostoma vent from the pneumostoma while leaving the chest mount
secured to the chest of the patient; and (e) inserting a tube of a
second pneumostoma vent through the aperture and engaging the first
coupling with a second coupling of the second pneumostoma vent such
that the second pneumostoma vent is secured in the pneumostoma and
such that material entering or exiting the pneumostoma must pass
through a tube and flow control device of the second pneumostoma
vent.
Description
CLAIM TO PRIORITY
[0001] This application claims priority to all of the following
applications including: U.S. Provisional Application Ser. No.
61/029,830, filed Feb. 19, 2008, entitled "ENHANCED PNEUMOSTOMA
MANAGEMENT DEVICE AND METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE
PULMONARY DISEASE" (Attorney Docket No. LUNG1-06013US0);
[0002] U.S. Provisional Application Ser. No. 61/032,877, filed Feb.
29, 2008, entitled "PNEUMOSTOMA MANAGEMENT SYSTEM AND METHODS FOR
TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE" (Attorney
Docket No. LUNG1-06001US0);
[0003] U.S. Provisional Application Ser. No. 61/038,371, filed Mar.
20, 2008, entitled "SURGICAL PROCEDURE AND INSTRUMENT TO CREATE A
PNEUMOSTOMA AND TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE"
(Attorney Docket No. LUNG 1-06000US0);
[0004] U.S. Provisional Application Ser. No. 61/082,892, filed Jul.
23, 2008, entitled "PNEUMOSTOMA MANAGEMENT SYSTEM HAVING A COSMETIC
AND/OR PROTECTIVE COVER" (Attorney Docket No. LUNG1-06008US0);
[0005] U.S. Provisional Application Ser. No. 61/083,573, filed Jul.
25, 2008, entitled "DEVICES AND METHODS FOR DELIVERY OF A
THERAPEUTIC AGENT THROUGH A PNEUMOSTOMA" (Attorney Docket No.
LUNG1-06003US0);
[0006] U.S. Provisional Application Ser. No. 61/084,559, filed Jul.
29, 2008, entitled "ASPIRATOR FOR PNEUMOSTOMA MANAGEMENT" (Attorney
Docket No. LUNG1-06011US0);
[0007] U.S. Provisional Application Ser. No. 61/088,118, filed Aug.
12, 2008, entitled "FLEXIBLE PNEUMOSTOMA MANAGEMENT SYSTEM AND
METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE"
(Attorney Docket No. LUNG1-06004US0);
[0008] U.S. Provisional Application Ser. No. 61/143,298, filed Jan.
8, 2009, entitled "METHODS AND APPARATUS FOR THE CRYOTHERAPY
CREATION OR RE-CREATION OF PNEUMOSTOMY" (Attorney Docket No.
LUNG1-06006US0); and
[0009] U.S. Provisional Application Ser. No. 61/151,581, filed Feb.
11, 2009, entitled "SURGICAL INSTRUMENTS AND PROCEDURES TO CREATE A
PNEUMOSTOMA AND TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE"
(Attorney Docket No. LUNG1-06002US0).
[0010] All of the afore-mentioned applications are incorporated
herein by reference in their entireties.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0011] This application is related to all of the above provisional
applications and all the patent applications that claim priority
thereto including:
[0012] This application is related to all of the following
applications including U.S. patent application Ser. No. 12/______,
filed Feb. 18, 2009, entitled "ENHANCED PNEUMOSTOMA MANAGEMENT
DEVICE AND METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY
DISEASE" (Attorney Docket No. LUNG1-06013US1);
[0013] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "PNEUMOSTOMA MANAGEMENT DEVICE FOR TREATMENT OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE" (Attorney Docket No.
LUNG1-06001US1);
[0014] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "TWO-PHASE SURGICAL PROCEDURE FOR CREATING A
PNEUMOSTOMA TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE"
(Attorney Docket No. LUNG1-06000US1);
[0015] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "ACCELERATED TWO-PHASE SURGICAL PROCEDURE FOR
CREATING A PNEUMOSTOMA TO TREAT CHRONIC OBSTRUCTIVE PULMONARY
DISEASE" (Attorney Docket No. LUNG1-06000US2);
[0016] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "SINGLE-PHASE SURGICAL PROCEDURE FOR CREATING A
PNEUMOSTOMA TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE"
(Attorney Docket No. LUNG1-06000US3);
[0017] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "PERCUTANEOUS SINGLE-PHASE SURGICAL PROCEDURE FOR
CREATING A PNEUMOSTOMA TO TREAT CHRONIC OBSTRUCTIVE PULMONARY
DISEASE" (Attorney Docket No. LUNG1-06000US4);
[0018] U.S. patent application Ser. No. 12/______, filed Feb. 13,
2009, entitled "PNEUMOSTOMA MANAGEMENT SYSTEM HAVING A COSMETIC
AND/OR PROTECTIVE COVER" (Attorney Docket No. LUNG1-06008US1);
[0019] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "DEVICES AND METHODS FOR DELIVERY OF A THERAPEUTIC
AGENT THROUGH A PNEUMOSTOMA" (Attorney Docket No.
LUNG1-06003US1);
[0020] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "ASPIRATOR FOR PNEUMOSTOMA MANAGEMENT" (Attorney
Docket No. LUNG1-06011US1);
[0021] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "ASPIRATOR AND METHOD FOR PNEUMOSTOMA MANAGEMENT"
(Attorney Docket No. LUNG1-06011US2);
[0022] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "FLEXIBLE PNEUMOSTOMA MANAGEMENT SYSTEM AND METHODS
FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE" (Attorney
Docket No. LUNG1-06004US1);
[0023] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "METHODS AND DEVICES FOR FOLLOW-UP CARE AND
TREATMENT OF A PNEUMOSTOMA" (Attorney Docket No.
LUNG1-06006US1);
[0024] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "SURGICAL INSTRUMENTS FOR CREATING A PNEUMOSTOMA AND
TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE" (Attorney Docket
No. LUNG1-06002US1);
[0025] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "ONE-PIECE PNEUMOSTOMA MANAGEMENT SYSTEM AND METHODS
FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE" (Attorney
Docket No. LUNG1-06017US1);
[0026] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "PNEUMOSTOMA MANAGEMENT SYSTEM WITH SECRETION
MANAGEMENT FEATURES FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY
DISEASE" (Attorney Docket No. LUNG1-06019US1);
[0027] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "MULTI-LAYER PNEUMOSTOMA MANAGEMENT SYSTEM AND
METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE"
(Attorney Docket No. LUNG1-06022US1);
[0028] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "VARIABLE LENGTH PNEUMOSTOMA MANAGEMENT SYSTEM FOR
TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE" (Attorney
Docket No. LUNG1-06023US1); and
[0029] U.S. patent application Ser. No. 12/______, filed Feb. 18,
2009, entitled "SELF-SEALING DEVICE AND METHOD FOR DELIVERY OF A
THERAPEUTIC AGENT THROUGH A PNEUMOSTOMA" (Attorney Docket No.
LUNG1-06025US1).
[0030] All of the afore-mentioned applications are incorporated
herein by reference in their entireties. This patent application
also incorporates by reference all patents, applications, and
articles discussed and/or cited herein.
BACKGROUND OF THE INVENTION
[0031] In the United States alone, approximately 14 million people
suffer from some form of Chronic Obstructive Pulmonary Disease
(COPD). However an additional ten million adults have evidence of
impaired lung function indicating that COPD may be significantly
underdiagnosed. The cost of COPD to the nation in 2002 was
estimated to be $32.1 billion. Medicare expenses for COPD
beneficiaries were nearly 2.5 times that of the expenditures for
all other patients. Direct medical services accounted for $18.0
billion, and indirect cost of morbidity and premature mortality was
$14.1 billion. COPD is the fourth leading cause of death in the
U.S. and is projected to be the third leading cause of death for
both males and females by the year 2020.
[0032] Chronic Obstructive Pulmonary Disease (COPD) is a
progressive disease of the airways that is characterized by a
gradual loss of lung function. In the United States, the term COPD
includes chronic bronchitis, chronic obstructive bronchitis, and
emphysema, or combinations of these conditions. In emphysema the
alveoli walls of the lung tissue are progressively weakened and
lose their elastic recoil. The breakdown of lung tissue causes
progressive loss of elastic recoil and the loss of radial support
of the airways which traps residual air in the lung. This increases
the work of exhaling and leads to hyperinflation of the lung. When
the lungs become hyperinflated, forced expiration cannot reduce the
residual volume of the lungs because the force exerted to empty the
lungs collapses the small airways and blocks air from being
exhaled. As the disease progresses, the inspiratory capacity and
air exchange surface area of the lungs is reduced until air
exchange becomes seriously impaired and the individual can only
take short shallow labored breaths (dyspnea).
[0033] The symptoms of COPD can range from the chronic cough and
sputum production of chronic bronchitis to the severe disabling
shortness of breath of emphysema. In some individuals, chronic
cough and sputum production are the first signs that they are at
risk for developing the airflow obstruction and shortness of breath
characteristic of COPD. With continued exposure to cigarettes or
noxious particles, the disease progresses and individuals with COPD
increasingly lose their ability to breathe. Acute infections or
certain weather conditions may temporarily worsen symptoms
(exacerbations), occasionally where hospitalization may be
required. In others, shortness of breath may be the first
indication of the disease. The diagnosis of COPD is confirmed by
the presence of airway obstruction on testing with spirometry.
Ultimately, severe emphysema may lead to severe dyspnea, severe
limitation of daily activities, illness and death.
[0034] There is no cure for COPD or pulmonary emphysema, only
various treatments, for ameliorating the symptoms. The goal of
current treatments is to help people live with the disease more
comfortably and to prevent the progression of the disease. The
current options include: self-care (e.g., quitting smoking),
medications (such as bronchodilators which do not address emphysema
physiology), long-term oxygen therapy, and surgery (lung
transplantation and lung volume reduction surgery). Lung Volume
Reduction Surgery (LVRS) is an invasive procedure primarily for
patients who have a localized (heterogeneous) version of emphysema;
in which, the most diseased area of the lung is surgically removed
to allow the remaining tissue to work more efficiently. Patients
with diffuse emphysema cannot be treated with LVRS, and typically
only have lung transplantation as an end-stage option. However,
many patients are not candidates for such a taxing procedure.
[0035] A number of less-invasive surgical methods have been
proposed for ameliorating the symptoms of COPD. In one approach new
windows are opened inside the lung to allow air to more easily
escape from the diseased tissue into the natural airways. These
windows are kept open with permanently implanted stents. Other
approaches attempt to seal off and shrink portions of the
hyperinflated lung using chemical treatments and/or implantable
plugs. However, these proposals remain significantly invasive and
are still in clinical trails. None of the surgical approaches to
treatment of COPD has been widely adopted. Therefore, a large unmet
need remains for a medical procedure that can sufficiently
alleviate the debilitating effects of COPD and emphysema.
SUMMARY OF THE INVENTION
[0036] In view of the disadvantages of the state of the art,
Applicants have developed a method for treating COPD in which an
artificial passageway is made through the chest wall into the lung.
An anastomosis is formed between the artificial passageway and the
lung by creating a pleurodesis between the visceral and parietal
membranes surrounding the passageway as it enters the lung. The
pleurodesis prevents air from entering the pleural cavity and
causing a pneumothorax (deflation of the lung due to air pressure
in the pleural cavity). The pleurodesis is stabilized by a fibrotic
healing response between the membranes. The artificial passageway
through the chest wall also becomes epithelialized. The result is a
stable artificial aperture through the chest wall which
communicates with the parenchymal tissue of the lung.
[0037] The artificial aperture into the lung through the chest is
referred to herein as a pneumostoma. A pneumostoma provides an
extra pathway that allows air to exit the lung while bypassing the
natural airways which have been impaired by COPD and emphysema. By
providing this ventilation bypass, the pneumostoma allows the stale
air trapped in the lung to escape from the lung thereby shrinking
the lung (reducing hyperinflation). By shrinking the lung, the
ventilation bypass reduces breathing effort (reducing dyspnea),
allows more fresh air to be drawn in through the natural airways
and increases the effectiveness of all of the tissues of the lung
for gas exchange. Increasing the effectiveness of gas exchange
allows for increased absorption of oxygen into the bloodstream and
also increased removal of carbon dioxide. Reducing the amount of
carbon dioxide retained in the lung reduces hypercapnia which also
reduces dyspnea. The pneumostoma thereby achieves the advantages of
lung volume reduction surgery without surgically removing a portion
of the lung or sealing off a portion of the lung.
[0038] In accordance with one embodiment, the present invention
provides a two piece pneumostoma management system which includes
two component pneumostoma management device having a
partially-implantable pneumostoma vent and a chest mount. The
partially-implantable pneumostoma vent is placed into a pneumostoma
through the chest mount to maintain the patency of the pneumostoma,
prevent the entry of foreign substances into the lung, control air
flow through the pneumostoma and collect any materials that may
exit the lung.
[0039] In accordance with one embodiment, the present invention
provides a two piece pneumostoma management system which includes a
partially-implantable pneumostoma vent and a chest mount. The
partially-implantable pneumostoma vent is placed into a pneumostoma
through an aperture in the chest mount. The partially-implantable
pneumostoma management device is designed such that every component
is larger than the aperture and thus cannot enter the
pneumostoma.
[0040] In accordance with one embodiment, the present invention
provides a two piece pneumostoma management system which includes a
partially-implantable pneumostoma vent and a chest mount. The
partially-implantable pneumostoma vent is placed into a pneumostoma
through an aperture in the chest mount. Insertion and removal tools
are provided for inserting the partially-implantable pneumostoma
vent into the chest mount and removing it from the chest mount.
[0041] In accordance with one embodiment, the present invention
provides a two piece pneumostoma management system which includes a
partially-implantable pneumostoma vent and a chest mount. An
insertion tool is used to position the partially-implantable
pneumostoma vent into a pneumostoma through an aperture in the
chest mount. The removal tool is designed such that it does not
release the pneumostoma management device after extraction thereby
protecting the non-sterile device from reuse.
[0042] In accordance with one embodiment, the present invention
provides a two piece pneumostoma management system which includes a
partially-implantable pneumostoma vent and a chest mount. The
partially-implantable pneumostoma vent is placed into a pneumostoma
through an aperture in the chest mount. The chest mount is secured
to the skin of the patient and is replaced every two days to one
week. The pneumostoma vent is replaced daily or when necessary.
[0043] In accordance with another embodiment of the present
invention, a method is provided for using the disclosed pneumostoma
management system to maintain the patency of the pneumostoma,
prevent the entry of foreign substances into the lung, control air
flow through the pneumostoma and collect any materials that may
exit the lung.
[0044] In accordance with another embodiment of the invention,
methods are provided utilizing insertion and removal tools to
insert and remove components of the pneumostoma management system
in a controlled and sterile manner.
[0045] Thus, various systems, components and methods are provided
for managing a pneumostoma and thereby treating COPD. Other
objects, features and advantages of the invention will be apparent
from drawings and detailed description to follow.
BRIEF DESCRIPTION OF THE DRAWINGS
[0046] The above and further features, advantages and benefits of
the present invention will be apparent upon consideration of the
present description taken in conjunction with the accompanying
drawings.
[0047] FIG. 1A shows the chest of a patient indicating alternative
locations for a pneumostoma that may be managed using the device
and methods of the present invention.
[0048] FIG. 1B shows a sectional view of the chest illustrating the
relationship between the pneumostoma, lung and natural airways.
[0049] FIG. 1C shows a detailed sectional view of a
pneumostoma.
[0050] FIG. 2A shows a perspective view of components of a
pneumostoma management system according to an embodiment of the
present invention.
[0051] FIG. 2B shows a sectional view of the components of FIG.
2A.
[0052] FIG. 2C shows a perspective view of the mounting flange of
FIG. 2A.
[0053] FIG. 2D shows a perspective view of the aperture plate of
the flange of FIG. 2C.
[0054] FIG. 2E shows a perspective view of the pneumostoma vent of
FIG. 2A.
[0055] FIG. 2F shows an exploded perspective view of the
pneumostoma vent of FIG. 2E.
[0056] FIG. 3A shows an insertion tool of a pneumostoma management
system according to an embodiment of the present invention.
[0057] FIGS. 3B-3F show aspects of the components and operation of
the insertion tool of FIG. 3A.
[0058] FIG. 4A shows a removal tool of a pneumostoma management
system according to an embodiment of the present invention.
[0059] FIGS. 4B-4F show aspects of the components and operation of
the removal tool of FIG. 4A.
[0060] FIGS. 5A-5D show steps and tools for applying a chest mount
according to embodiments of the present invention.
[0061] FIGS. 6A-6I show steps and tools for inserting a pneumostoma
vent and removing a pneumostoma vent according to embodiments of
the present invention.
[0062] FIGS. 7A and 7B show instruction for using a pneumostoma
management system in accordance with an embodiment of the present
invention.
[0063] FIGS. 8A and 8B show sterile packaging for components of the
pneumostoma management system in accordance with an embodiment of
the present invention.
[0064] FIGS. 9A-9D show alternative pneumostoma vent configurations
for pneumostoma management systems according to embodiments of the
present invention.
[0065] FIGS. 9E-9H show pneumostoma plugs according to embodiments
of the present invention.
[0066] FIGS. 10A-10E show alternative chest mount configurations
for pneumostoma management systems according to embodiments of the
present invention.
DETAILED DESCRIPTION OF THE INVENTION
[0067] The following description is of the best modes presently
contemplated for practicing various embodiments of the present
invention. The description is not to be taken in a limiting sense
but is made merely for the purpose of describing the general
principles of the invention. The scope of the invention should be
ascertained with reference to the claims. In the description of the
invention that follows, like numerals or reference designators will
be used to refer to like parts or elements throughout. In addition,
the first digit of a reference number identifies the drawing in
which the reference number first appears.
Pneumostoma Formation and Anatomy
[0068] FIG. 1A shows the chest of a patient indicating alternative
locations for creating a pneumostoma that may be managed using the
system and methods of the present invention. A first pneumostoma
110 is shown on the front of the chest 100 over the right lung 101
(shown in dashed lines). The pneumostoma is preferably positioned
over the third intercostal space on the mid-clavicular line. Thus
the pneumostoma 110 is located on the front of the chest between
the third and fourth ribs. Although the pneumostoma 110 is
preferably located between two ribs, in alternative procedures a
pneumostoma can also be prepared using a minithoracotomy with a rib
resection.
[0069] In FIG. 1A a second pneumostoma 112 is illustrated in a
lateral position entering the left lung 103 (shown in dashed
lines). The pneumostoma 112 is preferably positioned over the
fourth or fifth intercostal space under the left arm 104. In
general, one pneumostoma per lung is created; however, more or less
than one pneumostoma per lung may be created depending upon the
needs of the patient. In most humans, the lobes of the lung are not
completely separate and air may pass between the lobes.
[0070] A pneumostoma is surgically created by forming an artificial
channel through the chest wall and joining that channel with an
opening through the visceral membrane of the lung into parenchymal
tissue of the lung to form an anastomosis. The anastomosis is
joined and sealed by sealing the channel from the pleural cavity
using adhesives, mechanical sealing and/or pleurodesis. Methods for
forming the channel, opening, anastomosis and pleurodesis are
disclosed in applicant's pending and issued patents and
applications including U.S. patent application Ser. No. 10/881,408
entitled "Methods and Devices to Accelerate Wound Healing in
Thoracic Anastomosis Applications," U.S. patent application Ser.
No. 12/030,006 entitled "Variable Parietal/Visceral Pleural
Coupling," and U.S. Provisional Patent Application Ser. No.
61/038,371 entitled "Surgical Procedure And Instrument To Create A
Pneumostoma And Treat Chronic Obstructive Pulmonary Disease" which
are incorporated herein by reference in their entirety.
[0071] FIG. 1B shows a sectional view of chest 100 illustrating the
position of the pneumostoma 110. The parenchymal tissue 132 of the
lung 130 is comprised principally of alveoli 134. The alveoli 134
are the thin walled air-filled sacs in which gas exchange takes
place. Air flows into the lungs through the natural airways
including the trachea 136, carina 137, and bronchi 138. Inside the
lungs, the bronchi branch into a multiplicity of smaller vessels
referred to as bronchioles (not shown). Typically, there are more
than one million bronchioles in each lung. Each bronchiole connects
a cluster of alveoli to the natural airways. As illustrated in FIG.
1B, pneumostoma 110 comprises a channel through the thoracic wall
106 of the chest 100 between two ribs 107. Pneumostoma 110 opens at
an aperture 126 through the skin 114 of chest 100.
[0072] FIG. 1C shows a detailed sectional view of the pneumostoma
110. As illustrated in FIG. 1C, pneumostoma 110 comprises a channel
120 through the thoracic wall 106 of the chest 100 between the ribs
107. The channel 120 is joined to cavity 122 in the parenchymal
tissue 132 of lung 130. An adhesion or pleurodesis 124 surrounds
the channel 120 where it enters the lung 130. The thoracic wall 106
is lined with the parietal membrane 108. The surface of the lung
130 is covered with a continuous sac called the visceral membrane
138. The parietal membrane 108 and visceral membrane 138 are often
referred to collectively as the pleural membranes. Between the
parietal membrane 108 and visceral membrane 138 is the pleural
cavity (pleural space) 140. The pleural cavity usually only
contains a thin film of fluid that serves as a lubricant between
the lungs and the chest wall. In pleurodesis 124 the pleural
membranes are fused and/or adhered to one another eliminating the
space between the pleural membranes in that region.
[0073] An important feature of the pneumostoma is the seal or
adhesion surrounding the channel 120 where it enters the lung 130
which may comprise a pleurodesis 124. A pleurodesis 124 is the
fusion or adhesion of the parietal membrane 108 and visceral
membrane 138. A pleurodesis may be a complete pleurodesis in which
the entire pleural cavity 140 is removed by fusion of the visceral
membrane 138 with the parietal membrane 108 over the entire surface
of the lung 130. However, as shown in FIG. 1C, the pleurodesis is
preferably localized to the region surrounding the channel 120. The
pleurodesis 124 surrounding the channel 120 prevents air from
entering the pleural cavity 140. If air is permitted to enter
pleural cavity 140, a pneumothorax will result and the lung may
collapse.
[0074] Pleurodesis 124 can be created between the visceral pleura
of the lung and the inner wall of the thoracic cavity using
chemical methods including introducing into the pleural space
irritants such as antibiotics (e.g. Doxycycline or Quinacrine),
antibiotics (e.g. iodopovidone or silver nitrate), anticancer drugs
(e.g. Bleomycin, Mitoxantrone or Cisplatin), cytokines (e.g.
interferon alpha-2.beta. and Transforming growth factor-.beta.);
pyrogens (e.g. Corynebacterium parvum, Staphylococcus aureus
superantigen or OK432); connective tissue proteins (e.g. fibrin or
collagen) and minerals (e.g. talc slurry). A pleurodesis can also
be created using surgical methods including pleurectomy. For
example, the pleural space may be mechanically abraded during
thoracoscopy or thoracotomy. This procedure is called dry abrasion
pleurodesis. A pleurodesis may also be created using radiotherapy
methods, including radioactive gold or external radiation. These
methods cause an inflammatory response and or fibrosis, healing,
and fusion of the pleural membranes. Alternatively, a seal can be
created in an acute manner between the pleural membranes using
biocompatible glues, meshes or mechanical means such as clamps,
staples, clips and/or sutures. The adhesive or mechanical seal may
develop into pleurodesis over time. A range of biocompatible glues
are available that may be used on the lung, including
light-activatable glues, fibrin glues, cyanoacrylates and two part
polymerizing glues. Applicant's copending U.S. patent application
Ser. No. 12/030,006 entitled "VARIABLE PARIETAL/VISCERAL PLEURAL
COUPLING" discloses methods such as pleurodesis for coupling a
channel through the chest wall to the inner volume of the lung
without causing a pneumothorax and is incorporated herein by
reference for all purposes.
[0075] When formed, pneumostoma 110 provides an extra pathway for
exhaled air to exit the lung 130 reducing residual volume and
intra-thoracic pressure without the air passing through the major
natural airways such as the bronchi 138 and trachea 136. Collateral
ventilation is particularly prevalent in an emphysemous lung
because of the deterioration of lung tissue caused by COPD.
Collateral ventilation is the term given to leakage of air through
the connective tissue between the alveoli 134. Collateral
ventilation may include leakage of air through pathways that
include the interalveolar pores of Kohn, bronchiole-alveolar
communications of Lambert, and interbronchiolar pathways of Martin.
This air typically becomes trapped in the lung and contributes to
hyperinflation. In lungs that have been damaged by COPD and
emphysema, the resistance to flow in collateral channels (not
shown) of the parenchymal tissue 132 is reduced allowing collateral
ventilation to increase. Air from alveoli 134 of parenchymal tissue
132 that passes into collateral pathways of lung 130 is collected
in cavity 122 of pneumostoma 110. Pneumostoma 110 thus makes use of
collateral ventilation to collect air in cavity 122 and vent the
air outside the body via channel 120 reducing residual volume and
intra-thoracic pressure and bypassing the natural airways which
have been impaired by COPD and emphysema.
[0076] By providing this ventilation bypass, the pneumostoma allows
stale air trapped in the parenchymal tissue 132 to escape from the
lung 130. This reduces the residual volume and intra-thoracic
pressure. The lower intra-thoracic pressure reduces the dynamic
collapse of airways during exhalation. By allowing the airways to
remain patent during exhalation, labored breathing (dyspnea) and
residual volume (hyperinflation) are both reduced. Pneumostoma 110
not only provides an extra pathway that allows air to exit the lung
130 but also allows more fresh air to be drawn in through the
natural airways. This increases the effectiveness of all of the
tissues of the lung 130 and improves gas exchange. Increasing the
effectiveness of gas exchange allows for increased absorption of
oxygen into the bloodstream and also increased removal of carbon
dioxide. Reducing the amount of carbon dioxide retained in the lung
reduces hypercapnia which also reduces dyspnea. Pneumostoma 110
thus achieves many of the advantages sought by lung volume
reduction surgery without surgically removing a portion of the lung
or sealing off a portion of the lung.
[0077] Applicants have found that a pneumostoma management system
in accordance with embodiments of the present invention is
desirable to maintain the patency of the pneumostoma and control
flow of materials between the exterior of the patient and the
parenchymal tissue of the lung via a pneumostoma. The pneumostoma
management system includes a two-component pneumostoma management
device and may also include one or more of the associated tools,
packaging and methods described herein.
Pneumostoma Management Device
[0078] FIGS. 2A and 2B illustrate views of a pneumostoma management
device ("PMD") 200 in accordance with an embodiment of the present
invention. PMD 200 includes a chest mount 202 which may be mounted
to the skin of the patient and a pneumostoma vent 204 which is
fitted to the chest mount 202. In a preferred embodiment
pneumostoma vent 204 is mounted though an aperture 224 in chest
mount 202. Chest mount 202 has a first coupling that engages a
second coupling of the pneumostoma vent to releasably secure the
pneumostoma vent 204 to the chest mount 202. As will be further
described below, the join between the two components is engineered
so as to ensure that pneumostoma vent 204 cannot be over-inserted
into the lung if it separates from chest mount 202. In preferred
embodiments, pneumostoma vent 204 is formed from
biocompatible/implantable polymers or biocompatible/implantable
metals. In preferred embodiments, chest mount 202 is also formed
from biocompatible polymers or biocompatible metals. A patient will
typically wear a PMD at all times and thus the materials should
meet high standards for biocompatibility. Further description of
suitable materials for manufacturing a PMD are provided in the
Materials section below.
[0079] Pneumostoma vent 204 includes a tube 240 sized and
configured to fit within the channel of a pneumostoma. Tube 240 is
stiff enough that it may be inserted into a pneumostoma without
collapsing. Over time a pneumostoma may constrict and it is one
function of PMD 200 to preserve the patency of the channel of the
pneumostoma by resisting the natural tendency of the pneumostoma to
constrict. A crush recoverable material may be incorporated into
tube 240 in order to make it crush recoverable. In one example,
Nitinol, or another superelastic material, incorporated into tube
240 will give the tube collapse resistance and collapse recovery
properties.
[0080] Tube 240 of pneumostoma vent 204 is sufficiently long that
it can pass through the thoracic wall and into the cavity of a
pneumostoma inside the lung. Pneumostoma vent 204 is not however so
long that it penetrates so far into the lung that it might
interfere with a major blood vessel. Fortunately, the larger blood
vessels of the lung are located centrally and associated with the
bronchi. Thus, the pneumostoma will typically only be adjacent to
smaller peripheral blood vessels and risk from injury by the
pneumostoma vent is small.
[0081] The length of tube 240 required for a pneumostoma vent 204
varies significantly between different pneumostomas. A longer tube
240 is usually required in patients with larger amounts of body fat
on the chest. A longer tube 240 is usually required where the
pneumostoma is placed in the lateral position 112 rather than the
frontal position 110. Because of the variation in pneumostomas,
pneumostoma vents 204 are manufactured having tubes 240 in a range
of sizes and a patient is provided with a pneumostoma vent 204
having a tube 240 of appropriate length for the patient's
pneumostoma. Tube 240 may be from 30 to 120 mm in length and from 5
mm to 20 mm in diameter depending on the size of a pneumostoma. A
typical tube 240 may be between 40 mm and 80 mm in length and
between 8 mm and 12 mm in diameter. In alternative embodiments a
pneumostoma vent 204 is made with a single length (such as 120 mm)
of tube 240 and tube 240 is then cut to the length appropriate for
a particular patient.
[0082] Tube 240 of pneumostoma vent 204 preferably comprises an
atraumatic tip 252 at the distal end as shown in FIGS. 2A and 2B.
(This application uses the terms proximal and distal regarding the
components of the pneumostoma management system in the conventional
manner. Thus, proximal refers to the end or side of a device
closest to the hand operating the device, whereas distal refers to
the end or side of a device furthest from the hand operating the
device.) Tip 252 may be rounded, beveled or curved in order to
reduce irritation or damage to the tissues of the pneumostoma or
lung during insertion or while in position. Where a single length
tube 240 is provided and subsequently cut to length it is desirable
that the tube be shaped such that at each of a plurality of cut
points cutting will generate an atraumatic tip. This can be
achieved, for example, by including a series of rounded narrow
points on tube 240.
[0083] The material and thickness of tube 240 of pneumostoma vent
204 is selected such that tube 240 is soft enough that it will
deform rather than cause injury to the pneumostoma or lung.
Pneumostoma vent 204 has an opening 254 in tip 252 of tube 240.
Opening 254 allows the entry of gases from the cavity of the
pneumostoma into lumen 258 of tube 240. Tube 240 is optionally
provided with one or more side openings (not shown) positioned near
tip 252 and/or along the length of tube 240 to facilitate the flow
of gas and/or mucous/discharge into lumen 258.
[0084] Pneumostoma vent 204 includes a cap 242 and a hydrophobic
filter 248 over the opening 255 in the proximal end of tube 240.
Hydrophobic filter 248 is positioned over the proximal opening 255
into lumen 258. Hydrophobic filter 248 is positioned and mounted
such that material moving between lumen 258 and the exterior of
pneumostoma vent 204 must pass through hydrophobic filter 248.
Hydrophobic filter 248 is preferably designed such that it may be
fits into a recess in cap 242. As shown in FIG. 2B, cap 242
comprises a recess 238 into which hydrophobic filter 248 may be
fit. Hydrophobic filter 248 may alternatively be fitted into cap
242 using a joint such as a threaded coupling or adhesive or, in
some cases, formed integrally with cap 242. Hydrophobic filter 248
may be made from a material such as medical grade GOR-TEX (W. L.
Gore & Associates, Inc., Flagstaff, Ariz.). As shown in FIG.
2B, a snap ring 243 locks cap 242 and hydrophobic filter 248 onto
the proximal end of tube 240.
[0085] Hydrophobic filter 248 serves several purposes. In general,
hydrophobic filter 248 controls the passage of solid or liquid
material between the lumen 258 and the exterior of cap 242. For
example, hydrophobic filter 248 prevents the flow of water into the
lumen 258 through proximal opening 255. Thus, a patient using PMD
200 may shower without water entering the lung through the
pneumostoma. Hydrophobic filter 248 may also be selected so as to
prevent the entry of microbes, pollen and other allergens and
pathogens into the lumen 258. Hydrophobic filter 248 also prevents
the exit of liquid and particulate discharge from lumen 258 to the
exterior of pneumostoma vent 204. This is desirable to prevent
contact between liquid and particulate discharge and clothing for
example.
[0086] Chest mount 202 connects to the proximal end of pneumostoma
vent 204. In one embodiment, illustrated in FIGS. 2A and 2B, chest
mount 202 comprises a flange 222 and an aperture 224. The aperture
224 is adapted and configured to receive the pneumostoma vent 204.
Chest mount 202 is designed to have a smooth surface and a low
profile so it is comfortable for the patient to wear. Chest mount
202 should be designed so as not to snag on the patient's clothing
or to restrict motion of the patient's arm (if placed in a lateral
pneumostoma 112). Flange 222 is significantly wider than
pneumostoma vent 204. Flange 222 thus comprises a contact surface
232 which contacts the skin of the patient surrounding the
pneumostoma and positions the aperture 224 over the opening of the
pneumostoma. Flange 222 is designed such that it is sufficiently
flexible that it can conform to the surface of the chest. Contact
surface 232 is also provided with a pad of biocompatible adhesive
234, such as a hydrocolloid adhesive, for securing flange 222 to
the skin of the patient. The adhesive 234 may be protected by a
protector sheet that is removed prior to use of flange 222.
Adhesive 234 should be selected so as to secure flange 222 to the
chest of the patient in the correct position relative to the
pneumostoma without causing undue irritation to the skin of the
patient. The adhesive need not create an air tight seal between
flange 222 and the skin of the patient. Suitable adhesive pads are
available commercially from Avery Dennison (Painesville, Ohio).
[0087] Referring now to FIG. 2C which shows a perspective view of
chest mount 202 without pneumostoma vent 204. Flange 222 is
generally circular but is provided with one or more tabs 236 to
facilitate application and removal of flange 222 from the skin of
the patient. As shown in FIG. 2C, chest mount 202 comprises an
aperture 224 through which tube 240 of pneumostoma vent 204 may be
inserted. Flange 222 is slightly convex on the upper surface 235.
Flange 222 includes a recess 226 into which cap 242 of pneumostoma
vent 204 may be press fit. Flange 222 is thick enough in the region
of aperture 224 to receive the cap 242 of pneumostoma vent 204 so
that the cap of pneumostoma vent 204 is flush with the upper
surface 235 of flange 222. Recess 226 forms a coupling adapted to
releasably secure the cap 242 of pneumostoma vent 204 into flange
222. As shown in FIGS. 2B and 2C, recess 226 has a lip 227 to
releasably secure the cap 242 of pneumostoma vent 204 into flange
222. However, other couplings may be used to releasably secure
pneumostoma vent 204 to chest mount 202 including clips, pins,
snaps, catches, threaded joints, temporary adhesive and the
like.
[0088] In a preferred embodiment, an aperture plate 228 is embedded
in the conformable polymer of flange 222. FIG. 2D shows a
perspective view of an aperture plate 228 that is embedded within
flange 222 of chest mount 202. Note that aperture plate 228
surrounds aperture 224 of chest mount 202. Aperture plate 228 is
made of a stiffer, less compliant material than flange 222 in order
that the dimensions of aperture 224 are tightly controlled. Because
aperture plate 228 is stiff enough that the size and shape of
aperture 224 remains stable even under any reasonably possible
application of force to chest mount 202.
[0089] Referring now to FIG. 2E which shows a perspective view of
pneumostoma vent 204 without chest mount 202. Cap 242 is attached
to the proximal end of tube 240. Hydrophobic filter 248 is
sandwiched between cap 242 and tube 240. An opening 244 in cap 242
communicates with the lumen 258 of tube 240 via hydrophobic filter
248. As shown in FIGS. 2B and 2E, cap 242 comprises a lip 246 which
releasably engages lip 227 of recess 226 of flange 222 to secure
pneumostoma vent 204 within the recess 226 of flange 222. Lip 246
forms a coupling element of pneumostoma vent 204 that cooperates
with recess 226 to releasably secure pneumostoma vent 204 into
chest mount 202 with tube 240 positioned through aperture 224.
[0090] FIG. 2F shows an exploded view of pneumostoma vent 204
showing the individual components of pneumostoma vent 204.
Hydrophobic filter 248 is sandwiched between tube 240 and cap 242.
Tube 240 has a flange 241 at its proximal end. Snap ring 243 slides
over tube 240. The inner diameter of snap ring 243 is too small to
pass over flange 241 thus when snap ring 243 is locked into cap
242, tube 240 is locked to cap 242. It should be noted that the
outer diameter of each of snap ring 243, hydrophobic filter 248,
flange 241 and cap 242 is larger than the diameter of aperture 224
of aperture plate 228. Aperture plate 228 is sufficiently stiff
that the dimensions of aperture 224 will not change even under
loads significantly higher than would be expected during use of the
device. Thus, snap ring 243, hydrophobic filter 248, flange 241 and
cap 242 cannot pass through aperture 224 into the pneumostoma.
Distal tip 252 of tube 240 and the body of tube 240 are small
enough to pass through aperture 224 however, flange 241 and/or cap
242 serve to limit the passage of tube 240 through aperture 224.
These safety features prevent unsafe entry of any of the components
of pneumostoma vent 204 into pneumostoma even in the unlikely event
of device failure. Likewise all the components of the chest mount
202 such as flange 222 and aperture plate 224 are significantly
larger than the aperture of a pneumostoma thus precluding passage
of any component of the chest mount 202 into a pneumostoma even in
the unlikely event of device failure.
Insertion Tool
[0091] The pneumostoma management system may also include insertion
and/or removal tools for use with pneumostoma vent 204. The tools
help control insertion and removal of pneumostoma vent 204 and also
help maintain sterility of pneumostoma vent 204 before and during
insertion into a pneumostoma. FIGS. 3A-3F show views of an
insertion tool 300 which forms part of the pneumostoma system
according to one embodiment of the invention.
[0092] Referring now to FIG. 3A which shows an external view of
insertion tool 300. Insertion tool 300 includes a casing 340,
having a handle 360 at the proximal end and a grasper 380 at the
distal end. The tool also comprises an end cap 320 at the distal
end of casing 340 (not shown in FIG. 3A). When handle 360 is pushed
up against the distal end of casing 340, grasper 380 is configured
to lock to the cap of a pneumostoma vent. When handle 360 is pulled
away from casing 340 in the direction of arrow 306, grasper 380 is
configured to release the cap of a pneumostoma vent. Insertion tool
300 includes an internal mechanism that allows handle 360 to be
moved away from casing 340 in the direction of arrow 306 one time
and then locks handle 360 in place. Thus handle 360 is a single use
device. Handle 360 is provided in sterile packaging, the
one-time-use lock protects the no-longer-sterile insertion tool
from reuse.
[0093] FIG. 3B shows a sectional view of insertion tool 300. Casing
340 has a central lumen 344 running from the proximal end to the
distal end. End cap 320 is designed such that it may be snap fit
into the proximal end of casing 340 to lock together the components
of insertion tool 300 without the use of adhesive. End Cap 320 has
a step 322 which is engaged by lip 342 of casing 340. End cap 320
has an opening 324 through which a portion of the handle 360 is
received. End cap 320 also has a tongue 326 that protrudes into
casing 340.
[0094] Handle 360 includes a mandrel 362. In this embodiment the
handle and mandrel are formed in one piece. Mandrel 362 comprises a
square tab 364 and a ramped tab 366. Tabs 364 and 366 are on
opposite sides of slot 368 in mandrel 362. Slot 368 is sized and
configured such that mandrel 362 is sufficiently flexible in the
region of tabs 364 and 366 for the tabs to be pushed towards each
other slightly by compressing slot 368. The portion of handle 360
external to casing 340 is too large to enter casing 340 thus
precluding over insertion.
[0095] Grasper 380 comprises four arms 382 attached to a tubular
section 381 (only two arms shown in sectional view). Between the
arms 382 is a space 384 for receiving mandrel 362. The space
narrows slightly towards the distal end of the arms 382 because
arms 382 ramp up slightly in thickness towards the distal end. On
the distal end of each of arm 382 is a wedge 390. In the tubular
section 381 of grasper 380 there is a proximal detent 386 and a
distal detent 388 for receiving ramped tab 366 of mandrel 362. In
the tubular section 381 of grasper 380 there is also a slot 392
opposite detents 386 and 388 for receiving square tab 366 of
mandrel 362. The proximal end of tubular section 381 has a lip 389
which engages a recess 305 of the casing to fix the location of
grasper 380 and preclude passage of grasper 380 through casing
340.
[0096] To assemble insertion tool 300, mandrel 362 is inserted
through opening 324 in end cap 320. Tabs 364, 366 are pushed
towards one another compressing slot 368 as the tabs pass through
opening 324 which would otherwise be too narrow to allow tabs 364,
366 to pass. Mandrel 362 is then inserted through the tubular
section 381 of grasper 380 and between arms 382 until ramped tab
366 is located in distal detent 388 and square tab 364is located in
slot 392. Casing 340 is then pushed over grasper 380 until step 322
of end cap 320 engages lip 312 at the proximal end of casing 340.
Note that for ease of manufacturing insertion tool comprises only
four components casing 340, grasper 380, handle 360 and end cap
320. Moreover, to ensure all failure modes are as safe as possible,
each of the grasper 380, handle 360 and end cap 320 is too large to
pass through casing 340 any further than is necessary for their
function.
[0097] Insertion tool 300 is assembled in its locked configuration
as shown in FIGS. 3B and 3C. In this locked configuration of the
insertion tool, as shown in FIG. 3B, mandrel 362 fills the space
between 384 between arms 382 locking wedges 390 outward as shown by
arrows 308. Ramped tab 366 of mandrel 362 is in distal detent 386
of tubular section 381. FIG. 3C shows a view of the distal end of
insertion tool 300 in the locked configuration note that each of
arms 382 has been forced to its outermost position by the presence
of mandrel 362 at the distal end of its travel in space 384.
[0098] To release insertion tool 300, handle 360 is pulled in the
direction shown by arrow 306 relative to casing 340. As shown in
FIG. 3D, ramped tab 366 is oriented such that the motion of handle
360 in the direction 306 compresses slot 368 allowing ramped tab
366 to pass out of distal detent 386. Square tab 364 rides in slot
392 so that mandrel 362 does not rotate relative to tubular section
381. When ramped tab 366 reaches proximal detent 388, the slot 368
is decompressed and ramped tab 366 is pushed into proximal detent
388. Note that ramped tab 366 is oriented such that it is caught in
proximal detent 388 and cannot be returned from proximal detent 388
to distal detent 386. The travel of square tab 364 is also limited
by tongue 326 of end cap 320 so as to prevent removal of handle 360
from casing 340. Thus, handle 360 is now fixed in the unlocked
configuration.
[0099] In this unlocked configuration, shown in FIGS. 3D, 3E and
3F, the distal end of mandrel 362 is retracted away from the distal
end of casing 340. Consequently space 384 is vacant between arms
382 of grasper 380. As a consequence, wedges 390 may move inward as
shown by arrows 310 because of the flexibility of arms 382 no
longer constrained by the presence of mandrel 362. FIG. 3E shows a
view of the distal end of insertion tool 300 in the unlocked
configuration note that each of arms 382 has moved to an inner
position because mandrel 362 has been withdrawn from the distal end
of space 384. FIG. 3F shows a close-up of the distal end of
insertion tool 300 showing how inward displacement of arms 382
because of retraction of mandrel 362 allows wedges 390 to disengage
a cap 242 of a pneumostoma vent 204. Thus, in this unlocked
configuration of the insertion tool 300, insertion tool 300
releases pneumostoma vent 204 after insertion into a
pneumostoma.
Removal Tool
[0100] The pneumostoma management system may also include insertion
and/or removal tools for use with pneumostoma vent 204. The tools
help control insertion and removal of pneumostoma vent 204 and also
help maintain sterility of pneumostoma vent 204 before and during
insertion into a pneumostoma. FIGS. 4A-4F show views of a removal
tool 400 which forms part of the pneumostoma system according to
one embodiment of the invention.
[0101] Referring now to FIG. 4A which shows an external view of
removal tool 400. Removal tool 400, in this embodiment, comprises
the same casing 340, grasper 380 and end cap 320 as insertion tool
300. The structural difference between removal tool, 400 and
insertion tool 300 is handle 460. The starting position for handle
460 is, as shown in FIG. 4A, spaced away from casing 340. In this
unlocked configuration grasper 380 may be inserted into the cap of
a pneumostoma vent. However when handle 460 is pushed against
casing 340 as shown by arrow 406, removal tool 400 changes to the
locked configuration and is secured to the cap of a pneumostoma
vent allowing the pneumostoma vent to be removed from a chest
mount. Removal tool 400 includes an internal mechanism that only
allows handle 460 to be moved towards casing 340 in the direction
of arrow 406 one time and then locks handle 460 in place. Thus
removal tool 400 is a single use device. When removal tool 400 is
secured to a pneumostoma vent for removal, the removal tool and
pneumostoma vent are locked to one another and are disposed of in
that from. The one-time-use lock protects the no-longer-sterile
removal tool and pneumostoma vent from reuse.
[0102] FIG. 4B shows a sectional view of removal tool 400. The
internal components of removal tool 400 are the same as for
insertion tool 300 with the exception of handle 460 and mandrel
462. Handle 460 and mandrel 462 are formed in one piece. Note that
mandrel 462 comprises a square tab 464 and a ramped tab 466. Tabs
464 and 466 are on opposite sides of slot 468 in mandrel 462. Slot
468 is sized and configured such that mandrel 462 is sufficiently
flexible in the region of tabs 464 and 466 for the tabs to be
pushed towards each other slightly by compressing slot 468.
However, in mandrel 462, ramped tab 466 is ramped in the opposite
direction to ramped tab 366 of the insertion tool. Moreover, ramped
tab 466, square tab 464 and slot 468 are located such that in the
unlocked configuration, ramped tab 466 occupies proximal detent 388
of grasper 380 and square tab 464 is at the proximal end of slot
392. Note that for ease of manufacturing, removal tool 400 and
insertion tool 300 share three out of four components. Thus, only
five different components (casing 340, grasper 380, handle 360,
handle 460 and end cap 320) are required to make both the insertion
tool 300 and removal tool 400. Moreover, to ensure all failure
modes are as safe as possible, each of the grasper 380, handle 360,
handle 460 and end cap 320 is too large to pass through casing 340
any further than is necessary for their function.
[0103] Removal tool 400 is assembled in the same way as insertion
tool 300; mandrel 462 is first inserted through opening 324 in end
cap 320. Tabs 464, 466 are pushed towards one another, compressing
slot 468 as the tabs pass through opening 324, which would
otherwise be too narrow to allow tabs 464, 466 to pass. Mandrel 462
is then inserted through the tubular section 381 of grasper 380 and
between arms 382 until ramped tab 466 is located in proximal detent
388 and square tab 464 is located in slot 392. Casing 340 is then
pushed over grasper 380 until step 322 of end cap 320 engages lip
312 at the proximal end of casing 340.
[0104] Removal tool 400 is assembled in its unlocked configuration
as shown in FIGS. 4B and 4C. In this unlocked configuration of the
removal tool 400, mandrel 462 does not fill the space 384 between
arms 382. Thus wedges 390 can move inward as shown by arrows 408.
Ramped tab 466 of mandrel 462 is in proximal detent 388 of tubular
section 381. FIG. 4C shows view of the distal end of removal tool
400 in the unlocked configuration. Note that each of arms 382 can
travel inwards because mandrel 462 is not at the distal end of its
travel in space 384.
[0105] To secure removal tool 400 to a pneumostoma tube, handle 460
is pushed in the direction shown by arrow 406 relative to casing
340. As shown in FIG. 4D, ramped tab 466 is oriented such that the
motion of handle 460 compresses slot 468 allowing ramped tab 466 to
pass out of proximal detent 388. Square tab 464 rides in slot 392
so that mandrel 462 does not rotate relative to tubular section
381. When ramped tab 466 reaches distal detent 386, the slot 468 is
decompressed and ramped tab 466 is pushed into distal detent 386.
Note that ramped tab 466 is oriented such that it is caught in
distal detent 386 and cannot be returned from distal detent 388 to
proximal detent 388. Thus, handle 460 is now fixed in the locked
configuration. The travel of square tab 464 is also limited by
tongue 326 of end cap 320 so as to prevent removal of handle 460
from casing 340.
[0106] In the locked configuration of the removal tool shown in
FIGS. 4D-F, the distal end of mandrel 462 is pushed into the distal
end of casing 340. Consequently mandrel 462 fills space 384 and
pushes arms 382 outward as shown by arrows 410. FIG. 4E shows view
of the distal end of removal tool 400 in the locked configuration.
Note that each of arms 382 has moved to its outer position because
mandrel 462 has been pushed to the distal end of space 384. FIG. 4F
shows a close-up of the distal end of removal tool 400 showing how
outward displacement of arms 382 by mandrel 462 causes wedges 390
to engage cap 242 of a pneumostoma vent 204. Thus, in this locked
configuration of removal tool 400, removal tool 400 is secured to
pneumostoma vent 204 allowing it to be removed from the
pneumostoma.
Materials
[0107] In preferred embodiments, pneumostoma vent 204 and chest
mount 202 of PMD 200 are formed from biocompatible polymers or
biocompatible metals. A patient will typically wear PMD 200 at all
times and thus the materials, particularly of tube 240, should meet
high standards for biocompatibility. In general preferred materials
for manufacturing PMD 200 are biocompatible thermoplastic
elastomers that are readily utilized in injection molding and
extrusion processing. As will be appreciated, other suitable
similarly biocompatible thermoplastic or thermoplastic polymer
materials can be used without departing from the scope of the
invention. Biocompatible polymers for manufacturing PMD may be
selected from the group consisting of polyethylenes (HDPE),
polyvinyl chloride, polyacrylates (polyethyl acrylate and
polymethyl acrylate, polymethyl methacrylate, polymethyl-coethyl
acrylate, ethylene/ethyl acrylate), polycarbonate urethane
(BIONATEG), polysiloxanes (silicones), polytetrafluoroethylene
(PTFE, GORE-TEX.RTM., ethylene/chlorotrifluoroethylene copolymer,
aliphatic polyesters, ethylene/tetrafluoroethylene copolymer),
polyketones (polyaryletheretherketone, polyetheretherketone,
polyetherether-ketoneketone, polyetherketoneetherketoneketone
polyetherketone), polyether block amides (PEBAX, PEBA), polyamides
(polyamideimide, PA-11, PA-12, PA-46, PA-66), polyetherimide,
polyether sulfone, poly(iso)butylene, polyvinyl chloride, polyvinyl
fluoride, polyvinyl alcohol, polyurethane, polybutylene
terephthalate, polyphosphazenes, nylon, polypropylene,
polybutester, nylon and polyester, polymer foams (from carbonates,
styrene, for example) as well as the copolymers and blends of the
classes listed and/or the class of thermoplastics and elastomers in
general. Reference to appropriate polymers that can be used for
manufacturing PMD 200 can be found in the following documents: PCT
Publication WO 02/02158, entitled "Bio-Compatible Polymeric
Materials;" PCT Publication WO 02/00275, entitled "Bio-Compatible
Polymeric Materials;" and, PCT Publication WO 02/00270, entitled
"Bio-Compatible Polymeric Materials" all of which are incorporated
herein by reference. Other suitable materials for the manufacture
of the PMD include medical grade inorganic materials such stainless
steel, titanium, ceramics and coated materials.
[0108] Additionally, the tube 240 of pneumostoma vent 204 may be
designed to deliver a pharmaceutically-active substance. For
purposes of the present disclosure, an "active pharmaceutical
substance" is an active ingredient of vegetable, animal or
synthetic origin which is used in a suitable dosage as a
therapeutic agent for influencing conditions or functions of the
body, as a replacement for active ingredients naturally produced by
the human or animal body and to eliminate or neutralize disease
pathogens or exogenous substances. The release of the substance in
the environment of pneumostoma vent 204 has an effect on the course
of healing and/or counteracts pathological changes in the tissue
due to the presence of pneumostoma vent 204. In particular, it is
desirable in some embodiments to coat or impregnate pneumostoma
vent 204 with pharmaceutically-active substances that preserve the
patency of pneumostoma and/or are antimicrobial in nature but that
do not unduly irritate the tissues of the pneumostoma.
[0109] In particular cases, suitable pharmaceutically-active
substances may have an anti-inflammatory and/or antiproliferative
and/or spasmolytic and/or endothelium-forming effect, so that the
functionality of the pneumostoma is maintained. Suitable
pharmaceutically-active substances include:
anti-proliferative/antimitotic agents including natural products
such as vinca alkaloids (i.e. vinblastine, vincristine, and
vinorelbine), paclitaxel, epidipodophyllotoxins (i.e. etoposide,
teniposide), antibiotics (dactinomycin (actinomycin D)
daunorubicin, doxorubicin and idarubicin), anthracyclines,
mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin,
enzymes (L-asparaginase which systemically metabolizes L-asparagine
and deprives cells which do not have the capacity to synthesize
their own asparagine); antiplatelet agents such as G(GP) IIb/IIIa
inhibitors and vitronectin receptor antagonists;
anti-proliferative/antimitotic alkylating agents such as nitrogen
mustards (mechlorethamine, cyclophosphamide and analogs, melphalan,
chlorambucil), ethylenimines and methylmelamines
(hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan,
nitrosoureas (carmustine (BCNU) and analogs, streptozocin),
trazenes--dacarbazinine (DTIC); anti-proliferative/antimitotic
antimetabolites such as folic acid analogs (methotrexate),
pyrimidine analogs (fluorouracil, floxuridine, and cytarabine),
purine analogs and related inhibitors (mercaptopurine, thioguanine,
pentostatin and 2-chlorodeoxyadenosine{cladribine}); platinum
coordination complexes (cisplatin, carboplatin), procarbazine,
hydroxyurea, mitotane, aminoglutethimide; hormones (i.e. estrogen);
anti-coagulants (heparin, synthetic heparin salts and other
inhibitors of thrombin); fibrinolytic agents (such as tissue
plasminogen activator, streptokinase and urokinase), aspirin,
dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory;
antisecretory (breveldin); anti-inflammatory: such as
adrenocortical steroids (cortisol, cortisone, fludrocortisone,
prednisone, prednisolone, 6a-methylprednisolone, triamcinolone,
betamethasone, and dexamethasone), non-steroidal agents (salicylic
acid derivatives i.e. aspirin; para-aminophenol derivatives i.e.
acetaminophen; indole and indene acetic acids (inaperturethacin,
sulindac, and etodalac), heteroaryl acetic acids (tolmetin,
diclofenac, and ketorolac), arylpropionic acids (ibuprofen and
derivatives), anthranilic acids (mefenamic acid, and meclofenamic
acid), enolic acids (piroxicam, tenoxicam, phenylbutazone, and
oxyphenthatrazone), nabumetone, gold compounds (auranofin,
aurothioglucose, gold sodium thiomalate); immunosuppressives:
(cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin),
azathioprine, mycophenolate mofetil); angiogenic agents: vascular
endothelial growth factor (VEGF), fibroblast growth factor (FGF);
angiotensin receptor blockers; nitric oxide donors; antisense
oligionucleotides and combinations thereof, cell cycle inhibitors,
mTOR inhibitors, and growth factor receptor signal transduction
kinase inhibitors; retenoids; cyclin/CDK inhibitors; HMG co-enzyme
reductase inhibitors (statins); silver compound and protease
inhibitors.
[0110] In some embodiments, the active pharmaceutical substance to
be coated upon or impregnated in the pneumostoma vent 204 is
selected from the group consisting of amino acids, anabolics,
analgesics and antagonists, anaesthetics, anti-adrenergic agents,
anti-asthmatics, anti-atherosclerotics, antibacterials,
anticholesterolics, anti-coagulants, antidepressants, antidotes,
anti-emetics, anti-epileptic drugs, anti-fibrinolytics,
anti-inflammatory agents, antihypertensives, antimetabolites,
antimigraine agents, antimycotics, antinauseants, antineoplastics,
anti-obesity agents, antiprotozoals, antipsychotics,
antirheumatics, antiseptics, antivertigo agents, antivirals,
appetite stimulants, bacterial vaccines, bioflavonoids, calcium
channel blockers, capillary stabilizing agents, coagulants,
corticosteroids, detoxifying agents for cytostatic treatment,
diagnostic agents (like contrast media, radiopaque agents and
radioisotopes), electrolytes, enzymes, enzyme inhibitors, ferments,
ferment inhibitors, gangliosides and ganglioside derivatives,
hemostatics, hormones, hormone antagonists, hypnotics,
immunomodulators, immunostimulants, immunosuppressants, minerals,
muscle relaxants, neuromodulators, neurotransmitters and
neurotrophins, osmotic diuretics, parasympatholytics,
para-sympathomimetics, peptides, proteins, psychostimulants,
respiratory stimulants, sedatives, serum lipid reducing agents,
smooth muscle relaxants, sympatholytics, sympathomimetics,
vasodilators, vasoprotectives, vectors for gene therapy, viral
vaccines, viruses, vitamins, oligonucleotides and derivatives,
saccharides, polysaccharides, glycoproteins, hyaluronic acid, and
any excipient that can be used to stabilize a proteinaceous
therapeutic
[0111] Hydrophobic filter 248 should be sufficiently porous to
allow air to exit through the filter. Materials for hydrophobic
filters are available commercially and filters can be fabricated
from any suitable hydrophobic polymer, such as tetrafluoroethylene,
PTFE, polyolefins, microglass, polyethylene and polypropylene or a
mixture thereof. In preferred examples, the hydrophobic filter is a
laminated tetrafluoroethylene e.g. TEFLON.RTM., (E.I. du Pont de
Nemours Co.) or GORE-TEX.RTM. (W.L. Gore, Inc.) of a controlled
pore size. In other examples the hydrophobic filter may comprise a
felted polypropylene; PTFE/polypropylene filter media. Hydrophobic
filter 248 may additionally comprise an antimicrobial, an
anti-bacterial, and/or an anti-viral material or agent.
[0112] Insertion tool 300 and removal tool 400 do not contact the
pneumostoma. Thus, the materials of insertion tool 300 and removal
tool 400 do not have to be biocompatible and implantable materials.
Suitable materials for making insertion tool 300 and removal tool
400 include medical grade metals, plastics, acrylics and resins. In
a preferred embodiment the insertion tool, removal tool and
alignment tools may be made from ABS
(Acrylonitrile-Butadiene-Styrene) plastic. In a preferred
embodiment the insertion and removal tool are made of the same
material as aperture plate 228 and cap 242.
Use of the Pneumostoma Management System
[0113] The pneumostoma management system is designed such that the
system may be used by a patient in a sterile manner. After creating
and healing of the pneumostoma the patient will be responsible for
applying and removing the chest mount 202 and the insertion,
removal and disposal of pneumostoma vent 204. The patient will
exchange one pneumostoma vent 204 for another and dispose of the
used pneumostoma vent 204. Pneumostoma vent 204 will be replaced
periodically, such as daily, or when necessary. The patient will be
provided with a supply of pneumostoma vent 204 by a medical
practitioner or by prescription. Chest mount 202 will also be
replaced periodically, such as weekly, or when necessary. The
patient will also be provided with a supply of chest mount 202 by a
medical practitioner or by prescription. A one week supply of
pneumostoma vent 204 (such as seven pneumostoma vents 204) may be
conveniently packaged together with one chest mount 202.
[0114] To use PMD 200, chest mount 202 is first positioned over a
pneumostoma and secured with adhesive to the skin of the patient.
In a preferred embodiment, the chest mount remains attached for up
to a week thereby avoiding irritation of the skin caused by daily
attachment and removal of a mount. FIG. 5A illustrates the
positioning of chest mount 202 over pneumostoma 110 and pneumostoma
112 of FIG. 1A. As shown in FIG. 3A the low profile of chest mount
202 allows it to be inconspicuously positioned on the chest 100 of
a patient in either the frontal 110 or lateral 112 locations. PMD
200 is designed so as not to interfere with the range of motion or
clothing of the patient. This is of importance for a device such as
PMD 200 which must be used continuously to be effective. Comfort
and ease of use are important if patient compliance with treatment
protocols is to be achieved. Chest mount may be positioned by the
patient by manual alignment of the aperture 224 of chest mount 202
with the aperture of the pneumostoma. Alternatively a pneumostoma
vent or an alignment tool may be used to align the chest mount.
[0115] In one embodiment, the chest mount 202 may be aligned with
the pneumostoma 110 using a pneumostoma vent 204 and optionally an
insertion tool 300. The chest mount 202 may be provided to the
patient with the pneumostoma vent 204 and optional insertion tool
as one assembly. Alternatively, the patient may insert the
pneumostoma vent 204 into the chest mount 202 prior to applying
chest mount 202 to the chest. The patient then manipulates the
chest mount by the tabs 236 or insertion tool 300. The patient
places the tip of pneumostoma vent 204 into the aperture 126 of the
pneumostoma 110 and pushes the pneumostoma vent 204 gently and
slowly into the pneumostoma 110. During insertion the patient lets
the pneumostoma vent 204 align itself with the channel 120 of the
pneumostoma 110 such that when the chest mount 202 contacts and
adheres to the skin 114 of the chest 100, the aperture 224 of the
chest mount 202 is perfectly aligned with the aperture 126 of the
pneumostoma 110. If an insertion tool 300 was used, the patient
then pulls gently on handle 360 to detach the alignment tool 300
from the pneumostoma vent 204, leaving the chest mount 202 and
pneumostoma vent 204 in place on the chest 100 of the patient.
[0116] Alternatively, an alignment tool may be used during
positioning of chest mount 202. FIGS. 5B and 5C show a chest mount
alignment tool 560 which aids positioning a chest mount 202 and
aligning the aperture 224 of the chest mount 202 with an aperture
of a pneumostoma. The alignment tool 560 comprises a handle section
562 joined to a mount engagement section 564 joined to a
pneumostoma alignment probe 566. The handle is designed to be
gripped by the patient while applying the chest mount 202. The
handle 562 allows the chest mount 202 to be manipulated without
direct handling of the chest mount 202 by the patient. This reduces
the risk of contaminating the chest mount 202 and pneumostoma 110.
Mount engagement section 564 is shaped similarly to the cap of a
pneumostoma vent 204 and is designed to fit into and engage the
recess 226 of a chest mount 202. Like the cap of a pneumostoma
vent, the mount engagement section 564 is too large to pass through
the aperture 224 of an aperture plate 228 and thus cannot be
inserted too far through the chest mount 202. However, the
pneumostoma alignment probe 566 fits through aperture 224 and
protrudes a short distance beyond the contact surface 232 of the
flange 222. Pneumostoma alignment probe 566 is preferably small
enough that it will be suitable for use with all patients.
Preferably the length of pneumostoma alignment probe 566 is less
than the length of the smallest available pneumostoma vent 204.
Alignment tool 560 may be provided preassembled with a chest mount
202 as shown in FIG. 5B.
[0117] As shown in FIG. 5C, to apply the chest mount 202 the
patient uses handle 562 to remove the chest mount 202 from its
sterile packaging. The patient then removes any protective covering
over the adhesive on the contact surface 232 of the chest mount
202. The patient then places the tip of pneumostoma alignment probe
566 into the aperture 126 of the pneumostoma 110 and pushes the
probe gently and slowly into the pneumostoma 110. During insertion
the patient lets the probe 566 align itself with the channel 120 of
the pneumostoma 110 such that when the chest mount 202 contacts and
adheres to the skin 114 of the chest 100, the aperture 224 of the
chest mount 202 is perfectly aligned with the aperture 126 of the
pneumostoma 110. The patient then pulls gently on handle 562 to
remove the alignment tool 500, leaving the chest mount 202 in place
on the chest 100 of the patient ready to receive a pneumostoma
vent. The alignment tool 500 is preferably formed in one piece for
ease of manufacturing and safety. The pneumostoma alignment probe
566 preferably has a atraumatic tip 568 which may be soft, and or
rounded so as to avoid causing injury or irritation to the
pneumostoma during insertion of the probe.
[0118] In an alternative embodiment, illustrated in FIG. 5D, an
alignment tool 510 includes only the mount engagement section 564
and pneumostoma alignment probe 566. In this embodiment, the mount
engagement section 564 has a recess similar to the recess in the
proximal end of a pneumostoma tube 202 for engaging a removal tool
400 as shown in FIG. 4F. The alignment tool is supplied
preassembled to a chest mount 202. To use this alignment tool 510,
the patient first secures the removal tool 400 to the alignment
tool 510. The patient then uses casing 340 or removal tool 400 to
remove the chest mount 202 from its sterile packaging. The patient
then removes any protective covering over the adhesive on the
contact surface of the chest mount 202. The patient then guides the
pneumostoma alignment probe into the pneumostoma channel 120 as
before. When the chest mount 202 is positioned correctly and
adhered to the skin of the chest, the patient removes the removal
tool 400 and pneumostoma alignment tool 500 in one piece by pulling
gently on the casing 340 of the removal tool 400 leaving the chest
mount in position on the chest of the patient. The patient the
discards the removal tool 400 and pneumostoma alignment tool 500
locked together as one unit.
[0119] FIG. 6A shows a pneumostoma vent 204 secured to an insertion
tool 300. In a preferred embodiment, pneumostoma vents 204 are
supplied to a patient in the configuration shown in FIG. 6A. Thus
when pneumostoma vent 204 is removed from its sterile packaging by
the patient, the patient only touches insertion tool 300 and does
not touch the pneumostoma vent 204. Note that insertion tool 300 is
in the locked configuration and insertion tool 300 is securely
attached to cap 242 of pneumostoma vent 204 by the grasper 380.
[0120] FIG. 6B shows insertion of a pneumostoma vent 204 through a
chest mount 202 into a pneumostoma. The patient grips insertion
tool 300 and pushes tube 240 of pneumostoma vent 204 through the
aperture in chest mount 202 in the direction of arrow 602 until the
cap 242 of pneumostoma vent 204 engages the chest mount 202 as
shown in FIG. 6C. In this position, cap 242 is secured by chest
mount 202. The patient pulls handle 360 in the direction of arrow
604. This causes insertion tool 300 to change to its unlocked
configuration. In the unlocked configuration, grasper 380 releases
cap 242 of pneumostoma vent 204. (See FIGS. 3D-F). This allows
insertion tool 300 to be removed leaving pneumostoma vent 204 in
the correct position as shown in FIG. 6D. Insertion tool 300 is now
fixed in the unlocked position and may be discarded.
[0121] FIG. 6D shows a sectional view through PMD 200 and
pneumostoma 110 showing the interaction of the PMD 200 with the
pneumostoma 110. Tube 240 of pneumostoma vent 204 fits snugly
within channel 120 of pneumostoma 110. Pneumostoma vent 204 thus
maintains the patency of channel 120. Tube 240 of pneumostoma vent
204 is sized and configured such that it penetrates through channel
120 into cavity 122 in the parenchymal tissue 132 of lung 130.
Chest mount 202 is secured to the skin 114 of the patient. Aperture
plate 228 engages cap 242 of pneumostoma vent 204 to prevent over
insertion of pneumostoma vent 204 into the pneumostoma. Adhesive
234 contacts skin 114 holding PMD 200 in position on the chest 100
of the patient. Because of the snug fit of tube 240 of pneumostoma
vent 204 within channel 120 and the contact between chest mount 202
and skin 114, PMD 200 effectively controls the movement of all
material (including solids, liquids and gases) in and out of the
pneumostoma. Air flows from cavity 122 of pneumostoma 110 into
lumen 258 of tube 240 of pneumostoma vent 204 as shown by arrow
606. From lumen 258, exhaled air flows through hydrophobic filter
248 and vents to atmosphere as shown by arrow 608.
[0122] The pneumostoma vent 204 is left in position in chest mount
202. After a day (or if otherwise necessary) pneumostoma vent 204
may be removed from chest mount 202 using a removal tool 400. As
shown in FIG. 6E, the patient inserts the grasper 380 of a removal
tool 400 in the direction of arrow 610 into the cap 242 of the
pneumostoma vent 204. When removal tool 400 is positioned as shown
in FIG. 6F, the patient pushes in handle 460 in the direction shown
by arrow 612. This causes removal tool 400 to change to the locked
configuration in which grasper 380 is securely attached to the cap
242 of pneumostoma vent 204 as shown in FIG. 6G (see also FIGS.
4D-F).
[0123] The patient may now pull casing 340 of removal tool 400 in
the direction of arrow 614 as shown in FIG. 6H. Because the grasper
380 of removal tool 400 is locked to the cap 242 of pneumostoma
vent 204 the pneumostoma vent 204 is removed from the chest mount
202. Pneumostoma vent 204 is removed completely from the
pneumostoma and remains locked to removal tool 400 as shown in FIG.
6I. Removal tool 400 and pneumostoma vent 204 may be discarded as a
single unit and a new pneumostoma vent 204 may be inserted into the
pneumostoma as shown beginning with FIG. 6A.
[0124] FIG. 7A provides a set of instructions for use (IFU) 720 for
replacement of a chest mount according to an embodiment of the
invention. At step 722, the patient obtains the replacement chest
mount and verifies that it is the correct size for his/her
pneumostoma. At step 724, the patient removes the prior chest mount
and disposes of it as appropriate. At step 726 the patient removes
a sterile cleaning swab from the chest mount package. At step 728
the patient cleans the area of the skin around the pneumostoma. The
patient cleans in a direction radially out from the pneumostoma. At
step 730 the patient inspects the tissue around the pneumostoma and
the pneumostoma for inflammation or injury. If injury or
inflammation is observed the patient should seek medical
advice.
[0125] At step 732 the patient removes a new disposable (or
sterilized reusable) chest mount from its packaging. At step 734
the patient removes the backing from the adhesive pad of the chest
mount. Care is taken during steps 732 and 734 to handle the chest
mount only by the tabs and not to touch the surface which will be
in contact with the pneumostoma. In embodiments having a
pneumostoma alignment tool, the patient can handle the chest mount
using the alignment tool rather than using the tabs of the chest
mount. At step 736 the patient applies the chest mount to the
pneumostoma aligning the aperture of the chest mount with the
aperture of the pneumostoma. Chest mount may be packaged with an
alignment tool to assist in positioning chest mount correctly. If
pain or injury is perceived during application the patient should
seek medical advice. The steps of IFU 720 may also be performed by
a caregiver or medical practitioner.
[0126] FIG. 7B provides a set of instruction for use (IFU) 740 for
replacement of a pneumostoma vent according to an embodiment of the
invention. At step 742, the patient obtains the replacement
pneumostoma vent and verifies that it is the correct size for
his/her pneumostoma. The packaging of the pneumostoma vent is
clearly marked with the length of the pneumostoma vent. In addition
the pneumostoma vent can be color coded either on the cap or tube
such that a particular color indicates a particular length of
pneumostoma vent. At step 744, the patient takes a removal tool,
inserts the grasper of the removal tool into the cap of the used
pneumostoma vent 204 and pushes in the handle to secure the removal
tool to the used pneumostoma vent. At step 746 the patient removes
the used pneumostoma vent by pulling on the casing of the removal
tool. At step 748 the patient inspects the pneumostoma for
inflammation or injury. The area around the pneumostoma and the
aperture of the chest mount may be cleaned at this point if mucus
or discharge is present. If injury or inflammation is observed the
patient should seek medical advice.
[0127] At step 750 the patient removes a new pneumostoma vent from
the packaging. Pneumostoma vent 204 is already attached to an
insertion tool so patient does not directly touch the pneumostoma
vent. Patient grips the casing of the insertion tool to install the
new pneumostoma vent. At step 752 the patient aligns the tube of
the new pneumostoma vent with the opening in the chest mount 202
and inserts the pneumostoma vent using the insertion tool until the
cap snaps into place. Care is taken during steps 750 and 752 to
handle the pneumostoma vent only by the insertion tool and not to
touch the sterile pneumostoma tube. At step 754 the patient
releases the insertion tool by pulling back on the handle to cause
it to enter the unlocked configuration. At step 756 the patient
removes the insertion tool and discards it. If pain or injury is
perceived during insertion of pneumostoma vent the patient should
seek medical advice. The steps of IFU 740 may also be performed by
a caregiver or medical practitioner.
Packaging for Pneumostoma Management System
[0128] The components of the pneumostoma management system are
preferably supplied to the patient in sterile packaging. In
preferred embodiments the components are supplied in packaging that
assists the patient in utilizing the components of the system in
the correct sequence. FIGS. 8A and 8B show an example of packaging
for a chest mount 202 and a pneumostoma vent 204 respectively.
[0129] Referring now to FIG. 8A which shows package 800 for chest
mount 202. Package 800 comprises a tray 810 and a top cover 820.
Tray 810 comprises a plurality of dimples 812, 814, 816 sized and
configured to fit the components provided in the package. In this
example, dimple 812 contains a first sterile cleaning swab 832,
dimple 814 contains a second sterile cleaning swab 834, and dimple
816 contains the chest mount 202. The top cover 820 is secured to
the surface of tray 810 with an adhesive seal that can be broken by
a patient peeling the adhesive from the opening tabs 822, 824. The
top cover may be printed with material that assists the patient in
the appropriate sequence of the steps for using the enclosed
components. For example, a patient opening the package shown in
FIG. 8A in peeling top cover 820 from package 800 first exposes
first sterile cleaning swab 832 for cleaning the pneumostoma, then
second sterile cleaning swab 834 for cleaning the pneumostoma, and
finally and chest mount 202 for application to the cleaned
pneumostoma. Thus the package provides the components to the
patient in the order required for use.
[0130] Referring now to FIG. 8B which shows package 850 for
pneumostoma vent 204. Package 850 comprises a tray 860 and a top
cover 880. Tray 860 comprises a plurality of dimples 862, 864 sized
and configured to fit the components provided in the package. In
this example, dimple 862 contains a removal tool 400, dimple 864
contains an insertion tool 300 assembled to a 65 mm pneumostoma
vent 204. The top cover 870 is secured to the surface of tray 860
with an adhesive seal that can be broken by a patient pealing the
adhesive from the opening tab 872. The top cover may be printed
with material that assists the patient in the appropriate sequence
of the steps for using the enclosed components. For example, a
patient opening the package shown in FIG. 8A in peeling top cover
870 from package 800 first exposes removal tool 400 for removing
the pneumostoma vent 204 to be replaced. The patient then exposes
the insertion tool 300 and pneumostoma vent 204. Thus the package
provides the components to the patient in the order required for
use. Additionally, the insertion tool 300 is made accessible to the
patient so that the patient does not handle pneumostoma vent 204
directly. Note that the top cover is clearly marked with a size
indicator 874 so that patient may confirm that pneumostoma vent 204
is the correct size for their pneumostoma prior to commencing the
replacement procedure.
[0131] As previously noted, it may be desirable to replace the
chest mount 202 only every few days so as to avoid unnecessary
irritation to the skin surrounding the pneumostoma. It may be
desirable to replace the pneumostoma vent 204 every day. Thus,
chest mount 204 is preferably provided in a separate sterile tray
from the chest mount 202. In preferred embodiments a weekly kit may
be provided having one chest mount 204 and seven pneumostoma vents
204. Thus, a weekly kit may be a single package including one of
package 800 of FIG. 8A and seven of package 850 of FIG. 8B.
Alternatively, the components may be provided as individual
components separately packaged. For example, cleaning and
moisturizing swabs may alternatively or additionally be packaged
separately and provided to patient. The insertion tool, removal
tool and pneumostoma vent may also be separately packaged.
Additional and Alternative Pneumostoma Management Device
Features
[0132] It is not necessary that a flow-control device be used in a
pneumostoma vent to form an airtight seal against the entry of air
into the lung through the pneumostoma. Indeed, air may enter the
lung through the pneumostoma between removal and reinsertion of the
pneumostoma vent 204. The pleurodesis of the pneumostoma prevents
the entry of air into the pleural cavity which would otherwise
cause pneumothorax. However, it is sometimes desirable to restrict
flow of air in through the pneumostoma so as to encourage a
reduction in hyperinflation and to preclude the aspiration of
solid, liquid or gas into the lung through the pneumostoma. Thus,
in alternative embodiments a pneumostoma vent may be provided with
a flow control device instead of, or in addition to, the
hydrophobic filter 248. The flow-control device may comprise a
one-way valve assembly such as a flapper valve, Heimlich valve,
reed valve or the like for allowing air to be exhaled with very low
resistance through the pneumostoma while restricting the flow of
air or other matter into the pneumostoma from outside the body. A
suitable flow-control device preferably includes only a small
number of components for ease of manufacturing and reliability and
should be designed such that it has no small parts which might be
aspirated through the pneumostoma.
[0133] FIGS. 9A and 9B show the cap of a pneumostoma vent 910 which
includes an integrated flow control device and hydrophobic filter.
Pneumostoma vent 910 includes tube 912, cap 914, snap ring 916 and
filter/valve plate 918. Tube 912 has an aperture 913 which is
aligned with a non-porous region 917 of the filter/valve plate 918.
Filter valve plate is free to move slightly within the cap 914 in
response to air pressure. As shown in FIG. 9A, when the air
pressure in tube 912 is higher than the air pressure outside of cap
914 the filter/valve plate 918 moves away from tube 912 and
aperture 913 thus allowing air to pass out of tube 912 and through
the porous hydrophobic filter region 919 of filter/valve plate 918
along path 908. As shown in FIG. 9B, when the air pressure outside
cap 914 is higher than the air pressure inside tube 912 the
filter/valve plate 918 moves towards tube 912 and aperture 913 thus
blocking aperture 913 with non-porous region 917 of the
filter/valve plate 918 and preventing air from entering tube 913
through the cap. Thus, the integrated flow control device and
hydrophobic filter allows air to exit pneumostoma vent 910 via the
filter but operates as a one-way valve to prevent entry of air
through the pneumostoma vent 910. Note also that, as before, all
parts of the cap and integrated valve/hydrophobic filter are too
large to fit though the aperture of a chest mount to be used with
the pneumostoma vent 910 thereby precluding any failure mode in
which a part of the pneumostoma vent is aspirated into the
lung.
[0134] Optionally the filter/valve plate 918 if FIGS. 9A and 9B may
be biased closed with a light spring force that pushes the late
into the closed position of FIG. 9B. The spring force is selected
so that it is readily overcome by the exhalation air pressure
allowing the filter/valve plate 918 to move to the position shown
in FIG. 9A during exhalation. In an alternative embodiment,
filter/valve plate 918 may be a flexible disc that is fixed at the
edges. During exhalation the center of filter/valve plate 918 bows
outwards away from aperture 913 allowing the escape of air. During
inhalation, the external air pressure pushes filter/valve plate 918
flat against aperture 913 thus blocking aperture 913 with
non-porous region 917 of the filter/valve plate 918 and preventing
air from entering tube 913 through the cap.
[0135] FIG. 9C shows an alternative pneumostoma vent 920 which has
features within tube 922 designed to encourage migration of
discharge such as mucus and sputum out of the lung and prevent it
from re-entering the lung. These features may include barbs/fins
that preferentially allow discharge to travel along and out of the
inner lumen of the tube. As shown in FIG. 9C the interior surface
of tube 922 is covered with an array of barbs 925 which point away
from the aperture 923 in the tube 922. Mucus and sputum that enters
tube 922 through aperture 923 is pushed towards cap 924 by air flow
during exhalation. When the patient inhales, some air may enter
through cap 924 however the mucus and sputum is inhibited from
traveling back towards aperture 923 by the shape of the barbs. Thus
discharge is collected in tube 922. The discharge is removed and
disposed of when pneumostoma vent 920 is replaced. Also shown in
FIG. 9C are external feature 927 such as rings or ridges which may
be utilized on a pneumostoma vent to make a better seal between the
exterior of the pneumostoma vent and the interior of the channel of
the pneumostoma.
[0136] FIG. 9D shows an alternative pneumostoma vent 930 which has
a plurality of side apertures 935 in order to facilitate entry of
gases and/or discharge from a pneumostoma into the lumen 938 of
tube 932. One or more side openings 935 may be provided along tube
940 and/or close to the distal tip 934. The side openings 935 may
be provided instead of, or in addition to, the opening 933 in the
end of distal tip 933. The side openings 935 permit gases and/or
discharge to enter lumen 938 even if one or more openings is
occluded by tissue or other matter.
[0137] The tube of a pneumostoma vent such as tube 932 may be
created from a porous material such that air may enter the lumen of
the tube through the wall of the tube. The porous tube wall may be
provided in addition to or instead of the presence of distal
opening 933 or side opening 935. The tube of pneumostoma vent such
as tube 932 may also be provided with features for maintaining the
patency of the pneumostoma as shown in U.S. patent application Ser.
No. 12/030,006 entitled "Variable Parietal/Visceral Pleural
Coupling" which is incorporated herein by reference.
[0138] FIGS. 9E and 9F shows views of a pneumostoma plug 940 which
may be used to protect the pneumostoma from the entry of foreign
material during times or activities when a pneumostoma vent is not
present in chest mount 202. Or when it is necessary or desirable to
close the pneumostoma for activities such as, for example,
spirometry testing of lung function or swimming. As shown in FIG.
9E, pneumostoma plug 940 includes a cover 942 for covering the
external aperture in chest mount 202. The cover 242 preferably
conforms to the outside surface 235 of chest mount 202 to form a
functional seal of the aperture. If the exterior surface of cover
942 is subjected to increased pressure such as by water pressure
when swimming, cover 942 is pushed into better contact with surface
235 making a better seal and precluding the entry of water.
[0139] Pneumostoma plug 940 has a recessed handle 946 or similar
gripping mechanism to allow plug 240 to be grasped by the patient
and removed from chest mount 202 when necessary. One or more tabs
948 may be provided on the periphery of cover 942 to allow the
cover to be grasped by the patient to remove pneumostoma plug 940.
Tabs 948 may be provided instead of or addition to handle 946. Plug
940 is however preferably low profile so as to avoid being caught
and removed accidentally during an activity.
[0140] Below cover 942 is a chest mount engagement section 950
(shown in FIG. 9F) which is shaped similarly to the cap of a
pneumostoma vent in order to engage the recess of the chest mount.
Chest mount engagement section ensures that pneumostoma plug 940
snaps into place in chest mount 202 and remains there until removed
by patient. Note that cover 942 and chest mount engagement section
950 are large enough to preclude pneumostoma plug 940 from passing
through the aperture of the chest mount 202.
[0141] The only region of pneumostoma plug 940 that can pass
through the aperture of the chest mount is stopple 952. Stopple 952
is sized and configured to penetrate through the aperture into the
pneumostoma and to fill the pneumostoma tightly so as to prevent
the entry or exit of material through the pneumostoma. Stopple 952
preferably has an atraumatic tip 954 which is soft, and or curved
to facilitate insertion of stopple 952 and reduce irritation to the
pneumostoma. Note that stopple 952 is relatively short compared to
a pneumostoma vent such that stopple 952 preferably does not
penetrate beyond the end of channel of pneumostoma. Stopple 952
preferably does not penetrate into cavity so as to preclude contact
of stopple 952 with lung parenchymal tissue during vigorous
activity. The surface of stopple 952 may also be provided with
surface features such as ridges (not shown) to make a better seal
of the pneumostoma.
[0142] FIGS. 9F and 9G illustrate an alternative pneumostoma plug
960 designed to operate in conjunction with a pneumostoma vent 204.
Pneumostoma plug 960 comprises a cover 962 designed to engage the
top surface 235 of a chest mount 202. Note that pneumostoma plug
960 is designed such that it will not fit through the aperture of
chest mount 202 even if pneumostoma vent 204 is absent. Pneumostoma
plug 960 is provided with a ring of releasable adhesive 964 to
secure it to the top surface 235 of chest mount 202. Pneumostoma
plug is provided with a handle 966 or tab 968 to facilitate
application or removal of pneumostoma plug 960. Pneumostoma plug
960 is designed to fill the portion of the recess of chest mount
202 not filled by pneumostoma vent 204. Unlike the pneumostoma plug
940 of FIGS. 9E-F, pneumostoma plug 960 does not include a stopple
952. During use of plug 960, the channel of a pneumostoma will
contain the tube 240 or pneumostoma vent 204. Pneumostoma plug 960
is non-porous and may be used to temporarily cover and/or seal a
pneumostoma vent 204 during brief activities such as e.g.
spirometry testing, showering or working in a dirty
environment.
[0143] FIGS. 10A-D illustrate alternative configurations of
adhesive on the contact surface 232 of a chest mount 202. Flanges
222 of each chest mount 202 have adhesive material 234 distributed
thereon. Adhesive materials may be hydrocolloid adhesives which
absorb moisture while retaining good adhesiveness. However, even
the best adhesives may cause irritation of the skin during
prolonged exposure. Tissue irritation may result from merely from
build up of moisture on the skin behind PMD 200 regardless of the
presence of any particular adhesive. However, the distribution of
adhesive 234 may be controlled so as to help reduce irritation to
the skin of the patient. One way to achieve this is by reducing the
amount of time any particular portion of skin is in contact with
adhesive and/or allowing the skin in regions behind PMD 200 to
"breathe" when not in contact with adhesive 234. Thus, in some
embodiments the adhesive may be provided in stripes or patches and
absent in other stripes or patches. The adhesive areas may also be
elevated slightly above the surface of flange 222 such that non
adhesive areas of flange 222 do not contact the skin but leave a
slight air gap through which air may circulate and/or moisture may
escape. The adhesive patches themselves may comprise a breathable
laminate and adhesive so that the prolonged attachment of the PMD
does not irritate the skin. Furthermore, a chest mount may be
provided with one or more tabs which are free of adhesive. These
tabs allow a patient to get a purchase on the chest mount to gently
peel the chest mount off the skin when it needs replacement. The
adhesive patches may be arranged differently on different chest
mounts so as to contact different regions of skin surrounding a
pneumostoma. Alternatively the arrangement of adhesive patches may
be the same on each chest mount but the registration of the patches
may be changed by chance or deliberately each time a chest mount is
replaced so that the adhesive patches contact different regions of
skin surrounding a pneumostoma.
[0144] Referring now to FIG. 10A where the contact surface 232 of a
flange 222 of a chest mount 1020 is shown. Adhesive pads 1034, 1035
are located on contact surface 232 around aperture 224. The
adhesive is selected so as to help maintain the correct position of
chest mount 1020 without causing undue irritation to the skin of
the patient. As shown in FIG. 10A, adhesive pads 1034, 1035 are
provided in two discrete spaced-apart regions. Each adhesive pad
1034, 1035 preferably comprises a laminate structure with an inner
plastic, paper or foam layer (e.g., closed-cell polyethylene foam)
sandwiched between layers of adhesive. The adhesive pads 1034, 1035
are elevated above contact surface 232 by the thickness of the
inner layer. Thus, only some portions of skin around a pneumostoma
will be in contact with adhesive each time chest mount 202 is
changed. Different chest mounts may be provided with different
arrangements of adhesive patches. For example a second chest mount
may have adhesive patches located in the empty areas 1036, 1037 of
contact surface 232 such that it will contact different areas of
skin. FIG. 10B shows a sectional view of chest mount 1020 along
line B-B. FIG. 10B shows that contact surface 232 is spaced apart
from the skin of the patient when chest mount 1020 is applied. Air
can circulate between the adhesive pads 1034, 1035. As previously
described, the adhesive pads may be protected by a protector sheet
that is removed prior to use of PMD 200.
[0145] Any medically approved water resistant pressure sensitive
adhesive may be used to attach the chest mount to the skin of the
patient, such as hydrocolloid adhesives, zinc oxide adhesives and
hydrogel adhesives. Particularly effective adhesives in providing
the desired adhesive properties to secure the chest mount to the
skin of the wearer without irritation are formed from cross-linking
polymers with a plasticizer to form a 3-dimensional matrix. Some
useful adhesives are disclosed in WO 00/07637, WO 00/45866 WO
00/45766 and U.S. Pat. No. 5,543,151 which are incorporated herein
by reference. The adhesive can be applied to the contact surface
232 of flange 222 by any means known in the art such as slot
coating, spiral, or bead application or printing.
[0146] Referring now to FIG. 10C where a different distribution of
adhesive on contact surface 232 of a chest mount 1040 is shown. As
shown in FIG. 10C, adhesive pads may be distributed in small
patches 1042. The adhesive patches 1042 may cover a less than 100%
of the contact area 232. As shown in FIG. 10C, adhesive patches
1042 cover approximately half of the contact surface 232 of chest
mount 1040. Adhesive patches preferably cover from 10% to 50% of
contact surface 232. With the distribution pattern of FIG. 10C all
chest mounts may have the same distribution of adhesive. Because
patches 1042 are small and evenly distributed, variations of the
orientation of placement of chest mount 1040 will randomize the
location of the patches 1042 relative to the skin of the patient
such that a particular region of skin is only in contact with
adhesive for a percentage of time similar to the percentage of
coverage.
[0147] FIG. 10D illustrates an alternative method for rotating the
portions of skin around a pneumostoma that are in contact with
adhesive. As shown in FIG. 10D, chest mount 1050 has eight radial
adhesive patches 1052. The patches are arranged in a regular
pattern such that the patches are interspersed with non-adhesive
areas 1054. As shown in FIG. 10D, adhesive patches 1052 cover
approximately half of the contact surface 232 of chest mount 1040.
Adhesive patches preferably cover from 10% to 50% of contact
surface 232. A tab 236 is aligned with one of the adhesive patches
1052. With the chest mount 1050 of FIG. 10D, the patient
deliberately changes the orientation of tab 236 relative to the
pneumostoma each time a chest mount is changed. By changing the
rotation of the chest mount 1050 the patient can change which
portions of skin are in contact with adhesive patches 1052.
[0148] The functional purpose of the chest mount is: providing an
aperture; positioning the aperture in alignment with a pneumostoma;
providing a contact surface with which to secure the chest mount to
the patient; and providing a coupling to releasably receive a
pneumostoma vent and secure the pneumostoma vent through the
aperture into the pneumostoma. Thus, different designs of chest
mount 1060 may be made without departing from the scope of the
invention. FIG. 10E illustrates an alternative design of a chest
mount 1060. Chest mount 1060 is formed in one piece and does not
comprise separate flange 222 and aperture ring 228 components. As
all the components of chest mount 1060 are made from the same
material, the desired mechanical properties of portions of chest
mount 1060 are achieved by changing design parameters. For example,
the desired conformability is achieved in the flange region 1062 of
chest mount 1060 by reducing the thickness of the material. Cavity
1064 allows for a reduced thickness of material while maintaining
the overall shape of chest mount 1060. The material of chest mount
1060 is also thicker in region 1066 in the vicinity of aperture 224
so as to make the material around aperture stiffer in order to
control the dimensions of aperture 224.
[0149] The foregoing description of preferred embodiments of the
present invention has been provided for the purposes of
illustration and description. It is not intended to be exhaustive
or to limit the invention to the precise forms disclosed. Many
embodiments were chosen and described in order to best explain the
principles of the invention and its practical application, thereby
enabling others skilled in the art to understand the invention for
various embodiments and with various modifications that are suited
to the particular use contemplated. It is intended that the scope
of the invention be defined by the claims and their
equivalents.
* * * * *